Principal Financial Group Inc Denali Therapeutics Inc. Transaction History

Principal Financial Group Inc

  • $172 Billion
  • Q4 2024

A detailed history of Principal Financial Group Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 1,130,963 shares of DNLI stock, worth $26.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,130,963
Holding current value
$26.4 Million
% of portfolio
0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 31, 2025
BUY
$20.24 - $31.58 $22.9 Million - $35.7 Million
1,130,963 New
1,130,963 $23 Million
Q3 2024

Oct 31, 2024
BUY
$20.96 - $31.05 $3.14 Million - $4.66 Million
149,939 Added 13.77%
1,238,476 $36.1 Million
Q2 2024

Jul 29, 2024
SELL
$14.96 - $23.22 $508,625 - $789,456
-33,999 Reduced 3.03%
1,088,537 $25.3 Million
Q1 2024

Apr 29, 2024
BUY
$15.83 - $23.35 $773,010 - $1.14 Million
48,832 Added 4.55%
1,122,536 $23 Million
Q4 2023

Feb 07, 2024
BUY
$16.2 - $23.18 $6.38 Million - $9.12 Million
393,626 Added 57.88%
1,073,704 $23 Million
Q3 2023

Nov 02, 2023
SELL
$20.63 - $30.17 $132,320 - $193,510
-6,414 Reduced 0.93%
680,078 $14 Million
Q2 2023

Aug 07, 2023
BUY
$23.37 - $32.96 $4.62 Million - $6.51 Million
197,531 Added 40.4%
686,492 $20.3 Million
Q1 2023

May 09, 2023
SELL
$21.91 - $32.67 $821,581 - $1.23 Million
-37,498 Reduced 7.12%
488,961 $11.3 Million
Q4 2022

Feb 09, 2023
SELL
$26.28 - $33.92 $510,147 - $658,455
-19,412 Reduced 3.56%
526,459 $14.6 Million
Q3 2022

Nov 09, 2022
BUY
$25.97 - $38.53 $7.22 Million - $10.7 Million
278,139 Added 103.89%
545,871 $16.8 Million
Q2 2022

Aug 10, 2022
SELL
$20.88 - $35.19 $26,559 - $44,761
-1,272 Reduced 0.47%
267,732 $7.88 Million
Q1 2022

May 09, 2022
SELL
$29.0 - $47.27 $1.78 Million - $2.9 Million
-61,271 Reduced 18.55%
269,004 $8.65 Million
Q4 2021

Feb 09, 2022
BUY
$42.59 - $55.02 $1.13 Million - $1.46 Million
26,448 Added 8.7%
330,275 $14.7 Million
Q3 2021

Nov 09, 2021
SELL
$48.48 - $78.23 $1.24 Million - $2 Million
-25,517 Reduced 7.75%
303,827 $15.3 Million
Q2 2021

Aug 10, 2021
SELL
$50.3 - $78.44 $413,616 - $645,012
-8,223 Reduced 2.44%
329,344 $25.8 Million
Q1 2021

May 10, 2021
BUY
$53.8 - $81.53 $7 Million - $10.6 Million
130,063 Added 62.68%
337,567 $19.3 Million
Q4 2020

Feb 08, 2021
BUY
$36.89 - $93.56 $182,937 - $463,964
4,959 Added 2.45%
207,504 $17.4 Million
Q3 2020

Nov 06, 2020
BUY
$23.13 - $38.84 $12,096 - $20,313
523 Added 0.26%
202,545 $7.26 Million
Q2 2020

Aug 05, 2020
SELL
$16.01 - $28.82 $35,718 - $64,297
-2,231 Reduced 1.09%
202,022 $4.89 Million
Q1 2020

May 12, 2020
SELL
$14.2 - $27.98 $293,315 - $577,954
-20,656 Reduced 9.18%
204,253 $3.58 Million
Q4 2019

Feb 05, 2020
BUY
$14.4 - $19.99 $88,502 - $122,858
6,146 Added 2.81%
224,909 $3.92 Million
Q3 2019

Nov 13, 2019
SELL
$15.32 - $21.92 $20,743 - $29,679
-1,354 Reduced 0.62%
218,763 $3.35 Million
Q2 2019

Aug 12, 2019
BUY
$18.5 - $28.14 $617,104 - $938,665
33,357 Added 17.86%
220,117 $4.57 Million
Q1 2019

May 10, 2019
BUY
$17.99 - $24.65 $14,571 - $19,966
810 Added 0.44%
186,760 $4.34 Million
Q4 2018

Feb 14, 2019
SELL
$13.88 - $21.75 $235 - $369
-17 Reduced 0.01%
185,950 $3.84 Million
Q3 2018

Nov 14, 2018
BUY
$12.46 - $21.74 $40,457 - $70,589
3,247 Added 1.78%
185,967 $4.04 Million
Q2 2018

Aug 13, 2018
BUY
$15.25 - $21.02 $820,755 - $1.13 Million
53,820 Added 41.75%
182,720 $0
Q1 2018

May 14, 2018
SELL
$15.36 - $24.8 $796,707 - $1.29 Million
-51,869 Reduced 28.69%
128,900 $2.54 Million
Q4 2017

Feb 13, 2018
BUY
$15.04 - $21.45 $2.72 Million - $3.88 Million
180,769
180,769 $2.83 Million

Others Institutions Holding DNLI

# of Institutions
226
Shares Held
119M
Call Options Held
60.6K
Put Options Held
48.4K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.13B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email